What effect would a 60‑unit dose of insulin degludec (Tresiba) 200 U/mL have on a patient without diabetes?

Severe, Life-Threatening Hypoglycemia Requiring Immediate Emergency Treatment

A 60-unit dose of Tresiba (insulin degludec 200 U/mL) in a patient without diabetes would cause severe, prolonged, and potentially fatal hypoglycemia lasting 42+ hours due to the ultra-long half-life (>25 hours) of this basal insulin analog. 1

Immediate Clinical Effects

The patient would develop profound hypoglycemia within 1-12 hours of injection, with effects persisting for at least 42 hours after a single dose 1. In non-diabetic individuals who maintain normal glucose homeostasis, this represents a massive insulin overdose that will overwhelm all physiological counter-regulatory mechanisms.

Expected Timeline of Hypoglycemia

• Onset: Median onset around 1 hour post-injection, with maximum glucose-lowering effect at approximately 12 hours 1
• Duration: Glucose-lowering effect lasts at least 42 hours after injection 1
• Steady-state considerations: While therapeutic steady-state occurs after 3-4 days of daily dosing, a single 60-unit dose will have prolonged effects 1

Life-Threatening Complications

Severe hypoglycemia causes neurocognitive impairment, seizures, loss of consciousness, permanent brain damage, and death 2. The mortality risk is substantial—studies show severe hypoglycemia is independently associated with higher mortality (OR 3.233,95% CI [2.251,4.644]; p < .0001) 2.

Neurological Sequelae

• Nonspecific neurologic symptoms initially
• Progression to seizures and loss of consciousness
• Permanent brain damage from prolonged glycopenia 2
• Cardiac arrest and hyperkalemia as secondary complications 2

Emergency Management Protocol

Immediate Actions

1. Stop any insulin source immediately
2. Administer 10-20 g of hypertonic (50%) dextrose IV, titrated based on initial glucose value 2
3. Recheck blood glucose in 15 minutes with additional dextrose as needed to achieve BG >70 mg/dL 2
4. Avoid overcorrection to prevent iatrogenic hyperglycemia 2

Dextrose Dosing Strategy

The guideline-recommended formula for patient-specific dextrose dosing: 50% dextrose dose in grams = [100 − BG] × 0.2 g 2. This typically results in 10-20 g IV dextrose administration 2.

Titrated 10% dextrose in 50-mL (5-g) aliquots every minute is preferred over bolus 50% dextrose to avoid overcorrection and associated complications including cardiac arrest 2.

Glucagon Considerations

Glucagon 1 mg IM is an alternative but has slower onset (achieving final BG of 167 mg/dL after 140 minutes vs. 8 minutes with IV dextrose) and causes nausea/vomiting 2. Given the ultra-long duration of insulin degludec, IV dextrose is strongly preferred 2.

Critical Monitoring Requirements

Continuous observation with glucose monitoring every 1-2 hours for at least 48-72 hours is mandatory given insulin degludec's 42+ hour duration of action 1. The patient requires:

• Hourly capillary glucose monitoring initially 3
• Continuous IV dextrose infusion likely needed for 48+ hours
• ICU-level monitoring for severe cases
• Electrolyte monitoring, particularly potassium (insulin causes hypokalemia) 1

Hypokalemia Management

Insulin overdose causes severe hypokalemia through cellular potassium uptake 1. Rapid 50% dextrose administration can worsen hyperkalemia paradoxically and has been associated with cardiac arrest 2. Potassium must be monitored and corrected appropriately 1.

Prolonged Recovery Period

After apparent clinical recovery, continued observation and additional carbohydrate intake are necessary to avoid recurrence of hypoglycemia 1. Given insulin degludec's ultra-long action profile, this observation period must extend at least 48-72 hours, far longer than with shorter-acting insulins.

The half-life exceeding 25 hours means glucose-lowering effects persist well beyond initial treatment 1, 4. The steady-state pharmacodynamic profile shows effects lasting at least 42 hours after the last of 8 once-daily injections 1—a single 60-unit dose in a non-diabetic patient will have similarly prolonged effects.

Special Considerations

This represents a medical emergency requiring immediate hospitalization. The ultra-long duration of insulin degludec (>42 hours) 1 makes this particularly dangerous compared to shorter-acting insulins. The patient cannot be safely managed outpatient and requires intensive inpatient monitoring with continuous IV dextrose availability for at least 48-72 hours.